Drugs / Tumor Associated Lymph node T cell
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06716619 | Feb 2025 → Dec 2026 expected | neoplasm | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
| Phase 1 | NCT06302062 | Jun 2023 → Dec 2025 overdue | neoplasm | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Associated Lymph node T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06302062 ↗ |
| Modality | Cell therapy | “TAL-T cell therapy” NCT06716619 ↗ |